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NFATc1 is a master regulator of RANKL-induced osteoclast differentiation and herein we investigate
the regulatory mechanism of NFATc1 in osteoclast activation. Inactivation of NFATc1 strongly atten-
uates RANKL-induced bone resorption and overexpression of a constitutively active form of NFATc1
in osteoclasts induces formation of actin rings and resorption pits on dentin slices. We demonstrate
that NFATc1 binds directly to the promoter regions of its target genes and induces expression of var-
ious genes, including LTBP3, ClC7, cathepsin K, MMP9, and c-Src, which are key players in bone
resorption. Thus, NFATc1 is essential for RANKL-induced osteoclast activation via up-regulation of
osteoclast-activating genes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The balance between osteoblasts and osteoclasts is essential for
normal skeletal formation and maintenance as well as mineral
homeostasis [1,2]. Osteoclasts are large multinucleated cells de-
rived from monocyte/macrophage precursors which can resorb
bone. Activation of these polykaryon cells is required for proper
bone resorption mediated by pro-resorptive cytokines such as IL-1.
Receptor activator of NF-jB ligand (RANKL) plays a key role in
osteoclast differentiation, fusion, and activation [3]. RANKL induces
c-Fos expression during osteoclastogenesis and the binding of
c-Fos to the NFATc1 promoter region leads to NFATc1 gene expres-
sion. NFATc1 auto-ampliﬁes its own expression by binding to its
own promoter region resulting in robust NFATc1 expression during
RANKL-induced osteoclast differentiation [4].
NFATc1-deﬁcient embryonic stem cells fail to differentiate into
osteoclasts in response to RANKL [5] suggesting that NFATc1 acts
as a key modulator of osteoclastogenesis. Recently, we have dem-
onstrated that NFATc1 plays a pivotal role in the osteoclast fusion
process via up-regulation of the dendritic cell-speciﬁc transmem-
brane protein (DC-STAMP) and the d2 isoform of vacuolar ATPase
V0 domain (Atp6v0d2) [6]. Recently, NFATc1 has been shown to
activate Atp6v0d2 via co-activation with MEF2 and Mitf [7]. In
addition to NFATc1’s role in osteoclast differentiation and fusion,chemical Societies. Published by E
ksungkim@hotmail.com (N.there is mounting evidence that NFATc1 also regulates osteoclast
activation. It has been shown that activation of NFATc1 increases
osteoclast formation and activation in vivo [8]. Although the regu-
latory mechanism of NFATc1 during osteoclast differentiation and
fusion is well deﬁned, little is known about mechanism by which
NFATc1 regulates osteoclast activation.
Previous studies demonstrated that osteoclast activation is
mediated by various genes, including c-Src [9], chloride channel
7 (ClC7) [10], cathepsin K [11], latent transforming growth factor
beta binding protein 3 (LTBP3) [12], and matrix metallopeptidase
9 (MMP9) [13]. Besides Atp6i [14], TRAP, integrins, and carbonic
anhydrase II are directly or indirectly involved in bone resorption
[15,16].
Herein, we provide clear evidence that NFATc1 plays a key role
in RANKL-induced osteoclast activation, and that NFATc1 directly
regulates various genes associated with osteoclast activation such
as: LTBP3, ClC7, cathepsin K, MMP9, and c-Src.
2. Materials and methods
2.1. Reagents
All cell culture media and supplements were obtained from Hy-
Clone (South Logan, UT). Soluble recombinant mouse RANKL was
puriﬁed from insect cells as described previously [17]. Recombinant
human M-CSF was a gift from D. Fremont (Washington University,
St. Louis, MO). TRIZOL was obtained from Invitrogen (San Diego,
CA). Cyclosporin Awas purchased fromCalbiochem (San Diego, CA).lsevier B.V. All rights reserved.
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The 5 kb promoter regions of LTBP3, ClC7, cathepsin K, c-Src and
MMP9 were prepared from DNA extracted from RAW264.7 cells by
long-range PCR ampliﬁcation with Expand Long Template PCR Sys-
tem (Roche Applied Sciences, Mannheim Germany) according to
the manufacturer’s instructions using following primers: LTBP3
sense, CTC GAG AAA TGA CAT AAC CAT GTA AAC ATT G; LTBP3
antisense, AAG CTT GCA GGG GAT CGA GTG TTG GTA GCA G;
ClC7 sense, GGT ACC TTC AAA AGC AAG AAA GTG GCA CTG; ClC7
antisense, CTC GAG GAC CAA ACT CAA CAA GAA CAG; cathepsin
K sense, GGT ACC AAT GAA ACT TAC TGT GAG ACT GAG; cathepsin
K antisense, CTC GAG TCG GAT AGG AAG CGT GGC TAC TGT G;
c-Src sense, GGT ACC ATT TGC TTT ACT TCG CAC CCA CTG G; c-Src
antisense, CTC GAG CGG AGA GAC AGA CCG AGA GAA AGG;
MMP9 sense, AGG CGA GTG AAG TGG TAC CCA CTG; MMP9 anti-
sense, CTC GAG AAA GCC AGG AGA GCC AGG AGC AG. The PCR prod-
ucts were then cloned into the pGL2 basic luciferase vector
(Promega, Madison, WI). The OSCAR reporter vector and expression
vectors for NFATc1 were previously described [18].
2.3. Osteoclast formation
Murine osteoclasts were prepared from bone marrow cells as
previously described [19]. In brief, bone marrow cells were cul-
tured in a-minimal essential medium (a-MEM) containing 10%
fetal bovine serum (FBS) with M-CSF (5 ng/ml) for 16 h. Non-
adherent cells were harvested and cultured for 3 days in the pres-
ence of M-CSF (30 ng/ml). Floating cells were removed and
adherent cells (bone marrow-derived macrophages; BMMs) were
used as osteoclast precursors. To generate osteoclasts, BMMs
(3  105 cells/well/96-well plate) were cultured with M-CSF
(30 ng/ml) and RANKL (100 ng/ml) for 4 days. Cultured cells were
ﬁxed and stained for TRAP as previously described [20]. TRAP-po-
sitive multinuclear cells [TRAP(+) MNCs], containing more than
three nuclei, were counted as osteoclasts.
2.4. Retroviral infection
To generate retroviral supernatant, retroviral vectors were
transfected into the Plat E packaging cell line (3  105 cells/well/
6-well plate) using FuGENE 6 (Roche Applied Sciences) [6,18]. Viral
supernatant was collected from cultured media 24–48 h after
transfection. BMMs (2  106 cells/well/6-well plate) were incu-
bated with viral supernatant for 8 h in the presence of 10 lg/mlFig. 1. The effect of NFATc1 inactivation in RANKL-induced bone resorption. Calvarial
(108 M) and PGE2 (106 M). Mature osteoclasts were isolated from the cultured cells, pla
or M-CSF/RANKL (100 ng/ml) in the absence or presence of cyclosporine A (CsA, 5 lg/
Number of pits formed on dentin slices was counted. Results are representative of at leas
of quadruplicate cultures.polybrene (Sigma–Aldrich, St., Louis, MO). After removing the viral
supernatant, BMMs were used to generate osteoclasts.
2.5. Pit formation assay and actin ring staining
To generate mature osteoclasts, calvarial osteoblasts (1  106
cells) and bone marrow cells (1  107 cells) were co-cultured for
6 days with vitamin D3 (108 M) and PGE2 (106 M) in 10 cm plates.
Mature osteoclasts isolated from cultured cells were plated on
dentine slices and cultured for an additional 24 h with M-CSF
(30 ng/ml) alone or with M-CSF/RANKL (100 ng/ml) in the absence
or presence of cyclosporine A (CsA, 5 lg/ml) as indicated in Fig. 1.
For the experiments shown in Fig. 2, BMMs were transduced with
either a control vector or a constitutively active NFATc1 (Ca-
NFATc1) retrovirus. Cells were plated on dentine slices and cultured
for an additional 6 days in the presence of M-CSF. The slices were
recovered, cleaned by ultrasonication in 0.5 M NH4OH to remove
adherent cells, and stained with accustain (Sigma–Aldrich) to visu-
alize resorption pits. For actin ring staining, cultured cells were
ﬁxed and stained with Texas red-X phalloidin (Invitrogen).
2.6. Semiquantitative RT-PCR
RT-PCR was performed as previously described [18]. In brief,
RT-PCR analysis was performed using cDNA from cultured sam-
ples. Total RNA was extracted from cultured cells using TRIZOL.
First strand cDNA was transcribed from 1 lg of RNA using
Superscript RT (Invitrogen) following the protocol provided by
the supplier. Primer sequences of TRAP, OSCAR, NFATc1, HPRT,
c-Src, cathepsin K, integrins, and ATP6i were previously described
[6,18].
2.7. Luciferase assay
For transfection of reporter plasmids, HEK 293T cellswere plated
on 6-well plates at a density of 2  105 cells/well 1 day before trans-
fection. A total of 500 ng of plasmid DNAwas mixed with FuGENE 6
and transfected into the cells following the manufacturer’s protocol
[18]. The amount of transfectedDNAwas held constant to 500 ng by
addition of empty vector DNA where necessary. After 48 h of trans-
fection, the cells were washed twice with PBS buffer and then lysed
in reporter lysis buffer. Luciferase activity was measured with a
luciferase assay system (Promega) according to the manufacturer’s
instructions. Luciferase activity was measured in triplicate,
averaged, and then normalized with b-galactosidase activity usingosteoblasts and bone marrow cells were co-cultured for 6 days with 1.25(OH)2D3
ted on dentin slices, and cultured for an additional 24 h with M-CSF (30 ng/ml) alone
ml). (A) The slices were stained with hematoxylin to visualize resorption pits. (B)
t three independent sets of similar experiments. Data are expressed as means ± S.D.
Fig. 2. The effect of NFATc1 overexpression on osteoclast-associated gene expression. BMMs were transduced with pMX-IRES-EGFP (control) or constitutively active NFATc1
(Ca-NFAT). (A) Transduced BMMs were cultured for 6 days with M-CSF alone on dentin slices. The slices were stained with hematoxylin to visualize resorption pits. (B)
Transduced BMMs were cultured for 6 days with M-CSF alone. Cultured cells were ﬁxed and stained with Texas red-X phalloidin. (C) Total RNA was collected from cultured
cells and analyzed by RT-PCR to assess the expression levels of the indicated genes.
Fig. 3. The effect of NFATc1 inactivation on RANKL-induced up-regulation of genes
involved in osteoclast activation. BMMs were cultured with M-CSF and RANKL in
the absence or presence of CsA for the indicated times. Total RNA was collected
from each time point. RT-PCR was performed to assess the expression of the
indicated genes.
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substrate.
2.9. Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed with a ChIP kit (Upstate Biotech-
nologies, Temecula, CA) as previously described [18]. The precipi-
tated DNA was subjected to PCR ampliﬁcation with primers
speciﬁc for the LTBP3, ClC7, cathepsin K, c-Src and MMP9 promoter
regions containing NFATc1-binding sites. The following primers
were used for PCR: LTBP3 sense, AAT GGG CAA AAG TTA ACA
GAC CT; LTBP3 antisense, AGG GAG AAG TGA GCA GTT GTT TT;
ClC7 sense, TTG TTG GGA AAG TTT TTA TCT ATC G; ClC7 antisense,
CTA GTC CTC CAA GAG ATG ATA TGG A; cathepsin K sense, AGT
CTC CTA GAT CAA CAG CCT TTT T; cathepsin K antisense, TCT
TCA GAA GCC CTG TAA TAA CTG T; c-Src sense, AAA GTT TAT
GCT TTG AAG CTC TCT G; c-Src antisense, CTC CAT GCC TAA GAT
TTG TCT AAT G; MMP9 sense, AAG CTT TCC TGA GTG GAG CAG;
MMP9 antisense, GCT CTT TGA GGC AGG ATT TG.
3. Results
3.1. NFATc1 inactivation attenuates RANKL-induced bone resorption
To investigate whether NFATc1 plays a role in osteoclast activa-
tion, the effect of NFATc1 inactivation on bone resorption was
examined. Mature osteoclasts isolated from co-culture of primary
calvarial osteoblasts and bone marrow cells were plated on dentin
slices and were cultured for an additional 24 h. Compared to con-
trol cultures, RANKL strongly induced pit formation (Fig. 1A and
B). However, RANKL-induced bone resorption was strongly attenu-
ated by cyclosporine A (CsA) which inhibits calcineurin activity
[21], and subsequently inhibits NFATc1 activation. These data sug-
gest that NFATc1 acts as an important regulator of osteoclast
activation.3.2. Exogenous expression of NFATc1 induces formation of actin rings
and resoprtion pits
It has been shown that overexpression of constitutively active
NFATc1 in BMMs induces osteoclast differentiation and fusion
even in the absence of RANKL [5]. Therefore, we examined whether
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pared to control cells, exogeneous expression of NFATc1 in osteo-
clasts strongly induced pit formation (Fig. 2A). In addition,
NFATc1 over-expressing osteoclasts caused the formation of actin
rings which is important for bone resorption. These data indicate
that NFATc1 alone is sufﬁcient to induce bone resorption.
Next, we examined the expression patterns of various genes by
RT-PCR and found that NFATc1 overexpression of induced expres-
sion of various osteoclast-associated genes such as tartrate-resis-
tant acid phosphatase (TRAP) and osteoclast-associated receptor
(OSCAR); as well as known osteoclast-activating genes such as
ATP6i, LTBP3, ClC7, c-Src, cathepsin K, carbonic anhydrase II, and
MMP9 (Fig. 2C). Together, these data imply that NFATc1 is an
important mediator of osteoclast activation through up-regulation
of various osteoclast-activating genes.
3.3. Inactivation of NFATc1 attenuates RANKL-induced up-regulation
of osteoclast-activating genes
Given that RANKL induces osteoclast activation, we examined
whether RANKL could induce the expression of genes known to
be associated with osteoclast activation and function. As shownFig. 4. NFATc1 directly binds to the promoter region of genes associated with osteoclast
vectors and increasing amounts of NFATc1 (300 and 600 ng). Results are representative
and S.D. of triplicate samples. (B) ChIP assay. BMMs were cultured with M-CSF alone (BM
immune-precipitated with control IgG or anti-NFATc1 antibodies and subjected to PCR am
the indicated genes.in Fig. 3, RANKL strongly induced the expression of various osteo-
clast-activating genes, but this expression was abrogated by treat-
ment with CsA (Fig. 3). These data suggest that NFATc1 plays a
pivotal role in RANKL-induced up-regulation of key genes associ-
ated with osteoclast activation.
3.4. NFATc1 directly induces the expression of key genes associated
with osteoclast activation
To investigate whether NFATc1 directly causes the expression
of genes associated with osteoclast activation, we used a reporter
assay involving transient transfections into HEK 293T cells with a
reporter constructs containing the 5 kb promoter regions of LTBP3,
ClC7, c-Src, cathepsin K, and MMP9. NFATc1 increased luciferase
activity of these genes as well as OSCAR in a dose-dependent man-
ner (Fig. 4A).
To determine whether NFATc1 binds directly to the promoter
regions of these genes endogenously in osteoclasts, we performed
a chromatin immunoprecipitation (ChIP) assay. After immunopre-
cipitation with anti-NFATc1 or control antibody from BMMs or
osteoclasts, PCR was performed with primers speciﬁc for the pro-
moter regions of genes containing NFATc1-binding sites. A singleactivation. (A) HEK 293T cells were co-transfected with various luciferase reporter
of at least three independent sets of similar experiments. Data represent the means
M) or M-CSF/RANKL (osteoclasts, OC) for 3 days before cross-linking. Samples were
pliﬁcation with primers speciﬁc for NFATc1-binding sites in the promoter regions of
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cipitation with anti-NFATc1 antibody (Fig. 4B). These data indicate
that NFATc1 can directly regulate genes associated with osteoclast
activation.4. Discussion
Based on data from osteopetrotic mice, many genes appear to
be involved in bone degradation mediated by osteoclasts. Fully dif-
ferentiated osteoclasts recognize and physically attach to bone
during the degradation process. Mice lacking b3 integrin have an
osteosclerotic phenotype due to abnormal cytoskeleton organiza-
tion in osteoclasts [22]. Consistent with previous results [23], we
show that NFATc1 induces the expression of b3 integrin and
c-Src. Osteoclasts deﬁcient for c-Src exhibit reduced motility and
abnormal organization of the rufﬂe border and lack the cytoskele-
tal elements necessary for bone resorption. Our current data sug-
gest that NFATc1 is a key regulator of osteoclast migration and
adhesion to bone surface through induction of b3 integrin and
c-Src.
After attaching to bone, osteoclasts extrude protons and chlo-
ride ions through proton and chloride transporters onto the bone
surface and dissolve the inorganic components of the bone matrix.
Carbonic anhydrase II, ClC7 chloride channel, and Atp6i, the osteo-
clast-speciﬁc proton pump a3 subunit, are important for the pro-
cess of proton secretion. Mice deﬁcient for these genes develop
severe osteopetrosis because their osteoclasts cannot secrete acid
and thus cannot dissolve bone [10,14,24,25]. Thus, our data indi-
cate that NFATc1 also regulates osteoclast acidiﬁcation.
Once mineralized compartments are dissolved by acidiﬁcation,
osteoclasts degrade the organic matrix in bone by the secretion
of proteolytic enzymes such as cathepsin K and matrix metallopro-
teinases (MMPs). The osteopetrotic cathepsin K-deﬁcient mice
generate rufﬂed membranes and mobilize bone mineral, but fail
to degrade the collagen ﬁbers [26]. In addition, gelatinases such
as MMP9 have been shown to be involved in cytokine-induced
degradation of bone matrix [27]. LTBP3, an extracellular matrix
glycoprotein, is essential for activation of TGF-b and LTBP3 null
mice exhibit abnormally high bone mass due to defective bone
resorption [12]. Taken together, these data indicate that LTBP3 reg-
ulates the level of TGF-b in bone and cartilage, which leads to com-
promised osteoclast function. Thus, our observation suggests that
NFATc1 modulates degradation of organic matrix through up-reg-
ulation of cathepsin K, MMP9, and LTBP3.
Various transcription factors, including Mitf, PU.1 and NFATc1,
are involved in RANKL-induced osteoclastogenesis. Among these
transcription factors, NFATc1 appears to play a role in regulating
downstream gene expression in mature osteoclasts; whereas Mitf
and PU.1 are responsible for initiating induction of target genes
during RANKL-induced osteoclastogenesis [28]. Consistent with
this, our data clearly demonstrate that NFATc1 is important for
activation of mature osteoclasts through direct regulation of vari-
ous genes involved in osteoclast activation.
In this study, we provide the ﬁrst line of evidence that NFATc1
plays a pivotal role in osteoclast activation via up-regulation of
various genes responsible for osteoclast adhesion, migration, acid-
iﬁcation, degradation of inorganic and organic bone matrix. There-
fore, our data suggest that NFATc1 is a master modulator for
osteoclast activation as well as osteoclast fusion and maturation.
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